METABOLIC DISORDERS

Pharmidex can provide in vitro assays and in vivo animal models to investigate the efficacy of the compounds in metabolic disorders (obesity, diabetes, NASH) and kidney diseases including AKPKD (autosomal dominant polycystic kidney disease).

Obesity

  • Biomarkers analysis
  • Body weight glucose tolerance, insulin sensitivity and/or insulin tolerance
  • Diet induced NASH (Non-alcoholic Steatohepatitis)
  • Diet induced Obesity (DIO)
  • Duration : Maximum 40 weeks
  • Genetic models : Rat and Mice
  • Species: Rat, Mice
  • Routes of Administration: IV, PO, SC, IP, IN
  • Zucker fatty rats

Diabetes

  • Biomarkers analysis
  • Body weight glucose tolerance, insulin sensitivity and/or insulin tolerance
  • Chemically Induced Model (Streptozotocin, Alloxan)
  • Duration : Maximum 40 weeks
  • Genetic models : Rat and Mice Zucker Diabetic Fatty (ZDF) Rat, AKITA MICE, db/db.
  • Routes of Administration: IV, PO, SC, IP, IN
  • Species: Rat, Mice

Kidney Diseases

  • Allergen Induced Model (LPS)
  • Chemically Induced Model (Adriamycin, Folic acid)
  • Duration : Maximum 30 weeks
  • Genetic models : Rat and Mice
  • Routes of Administration: IV, PO, SC, IP, IN
  • Species: Rat, Mice
  • Tamoxifen Induced ADPKD
  • Urine analysis and imaging